Contract Pharma18h
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic
Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...
Ocean Biomedical advances in cancer immunotherapy
PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...
Medindia1d
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
Is your body resisting cancer treatment? Doctors list potential reasons for drug resistance
One of the most significant challenges in cancer treatment is the development of drug resistance by cancer cells, which often leads to treatment failure. When we say the body "resists" cancer ...
BioWorld3d
Trump’s executive orders stacking up, along with challenges
President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...
Too Old to Operate8d
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...
Frontiers8d
Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
Following publication, concerns were raised regarding the integrity of the images in the published figures. Specifically, unexpected similarity was detected between western blot images presented in ...
Medscape12d
Investigative Treatments for Moderate to Severe Psoriasis Reviewed
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
The American Journal of Managed Care13d
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
Medscape15d
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
On the other hand, mechanisms of acquired resistance to 'pathway-targeted' drugs, such as the various clinically active kinase inhibitors, have been somewhat more straightforward to elucidate and ...